Tirzepatide · research summary

Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic program.

American journal of preventive cardiology · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Retrospective chart review of a single-center multidisciplinary cardiometabolic program
“We conducted a retrospective chart review of patients who were prescribed a Glucagon like peptide −1 Receptor agonist (GLP-1 RA) or a Glucagon like peptide −1 Receptor agonist/ Glucose-dependent insulinotropic polypeptide (GLP-1/GIP) co-agonist in our clinic from September 2023 through July 2025.”

Subjects

Cardiology patients with BMI > 30 and comorbidities including Type 2 Diabetes, coronary artery disease, Atrial Fibrillation, or Congestive Heart Failure
“Patients seen within the cardiology practice, who had a body mass index (BMI) greater than 30 and with Type 2 Diabetes (T2D), coronary artery disease (CAD), Atrial Fibrillation (Afib) or Congestive Heart Failure (CHF) were referred.”

Sample size

69 patients with documented follow-up visits
“Of these, 69 patients had documented at least 1 follow-up visit and were included in the present analysis.”

Duration

Data collected from September 2023 through December 2025, with follow-up data available up to more than 2 years
“Data was collected from date of prescription till December 2025.”

Reported findings

Median percent weight loss increased to 11.7% at >1 year and 13.7% at >2 years
“Median percent weight loss increased from 6.98 ± 3.2 % by 6 months to 9.11 ± 7.3 % by 12 months, to 11.7 ± 6.5% at >1 year and 13.7% ± 7.8 at > 2 years.”
Discontinuation rate was 7.25%, with 71.0% of patients continued on the same medication
“49 patients (71.0%) were continued on the same medication, 2 (2.9%) had therapy paused with a plan to resume within weeks, and 5 (7.25%) stopped therapy completely.”

Limitations stated by the authors

Retrospective single-center design without a control group, data attrition at >2 years, and limited laboratory data availability
“First, the retrospective, single-center design without a concurrent control group precludes causality regarding observed outcomes. Secondly, data attrition limits the statistical reliability and generalizability of data at > 2-year period. Third, laboratory outcome data were available only for the subset of patients.”

Source: PubMed 42828252 · DOI 10.1016/j.ajpc.2026.101699 · all study summaries

Study type

Retrospective chart review of a single-center multidisciplinary cardiometabolic program

“We conducted a retrospective chart review of patients who were prescribed a Glucagon like peptide −1 Receptor agonist (GLP-1 RA) or a Glucagon like peptide −1 Receptor agonist/ Glucose-dependent insulinotropic polypeptide (GLP-1/GIP) co-agonist in our clinic from September 2023 through July 2025.”

Subjects

Cardiology patients with BMI > 30 and comorbidities including Type 2 Diabetes, coronary artery disease, Atrial Fibrillation, or Congestive Heart Failure

“Patients seen within the cardiology practice, who had a body mass index (BMI) greater than 30 and with Type 2 Diabetes (T2D), coronary artery disease (CAD), Atrial Fibrillation (Afib) or Congestive Heart Failure (CHF) were referred.”

Reported findings

Median percent weight loss increased to 11.7% at >1 year and 13.7% at >2 years

“Median percent weight loss increased from 6.98 ± 3.2 % by 6 months to 9.11 ± 7.3 % by 12 months, to 11.7 ± 6.5% at >1 year and 13.7% ± 7.8 at > 2 years.”

Discontinuation rate was 7.25%, with 71.0% of patients continued on the same medication

“49 patients (71.0%) were continued on the same medication, 2 (2.9%) had therapy paused with a plan to resume within weeks, and 5 (7.25%) stopped therapy completely.”

Limitations stated by the authors

Retrospective single-center design without a control group, data attrition at >2 years, and limited laboratory data availability

“First, the retrospective, single-center design without a concurrent control group precludes causality regarding observed outcomes. Secondly, data attrition limits the statistical reliability and generalizability of data at > 2-year period. Third, laboratory outcome data were available only for the subset of patients.”